Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13844518 | 0.83 | — | — | |
| SCHEMBL17247516 | 0.75 | RAB9A (0.39) | NPC1TP53PKMRAB9ASMN1; SMN2 | |
| SCHEMBL27345662 | 0.75 | ALDH1A1 (0.34) | RAB9ACNR1CNR2 | |
| SCHEMBL13193547 | 0.75 | CNR1 (0.31) | CNR1CNR2 | |
| SCHEMBL13028888 | 0.73 | ESR1 (0.33) | — | |
| SCHEMBL24434530 | 0.73 | CNR1 (0.35) | NPC1TP53PKMRAB9ASMN1; SMN2 | |
| SCHEMBL20356224 | 0.69 | CYP11B1 (0.32) | CNR1CNR2 | |
| SCHEMBL1913009 | 0.68 | CYP11B1 (0.39) | NPC1TP53PKMRAB9ASMN1; SMN2 | |
| SCHEMBL24799773 | 0.68 | NPC1 (0.39) | NPC1TP53PKMRAB9ASMN1; SMN2 | |
| SCHEMBL16390248 | 0.67 | NOS1 (0.42) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | P2RY1, P2RX7, P2RX1 | NPC1 1850/4885TP53 3966/4885PKM 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.